ペプチド抗生物質の市場規模、シェア、動向分析レポート：疾患別、投与経路別、製品別、流通チャネル別、地域別、セグメント予測、2025年～2030年

ペプチド抗生物質市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のペプチド抗生物質市場規模は2025～2030年にかけてCAGR 5.1%で拡大し、2030年には66億4,000万米ドルに達すると推定されています。

同市場は、ペプチド抗生物質セグメントでの研究開発活動の活発化と医薬品承認件数の多さなどの要因により、成長機会に恵まれると期待されています。さらに、抗菌薬耐性症例の急増や従来の抗生物質による副作用の可能性も、予測期間中に市場を牽引すると予想されます。

がんやその他の感染症の有病率の増加は、予測期間中の成長を促進すると予想されます。例えば、CDCによると、米国では2019年に59万9,589人の死亡とともに175万2,735人の新たながん患者が報告されました。人口10万人当たり、439人の新規症例が発見され、146人ががんが原因で死亡しました。さらに、Globocan 2020によると、英国では2020年に45万7,960人の新規患者が発生し、17万9,648人が死亡しました。最も多い悪性腫瘍タイプは、乳がん、前立腺がん、非ホジキンリンパ腫でした。

ペプチド抗生物質の中には、非ホジキンリンパ腫、ホジキンリンパ腫、ある種の皮膚悪性腫瘍などのがんの治療に使用されるものがあります。Globocan 2020によると、非ホジキンリンパ腫の患者数は54万4,352人、ホジキンリンパ腫の患者数は8万3,087人です。様々な既存製品の有効性は、医師の推奨により、より高い収益につながると予想されます。例えば、注射用BLEOMYCIN USPは、Streptomyces verticillusから単離された細胞毒性糖ペプチド抗生物質の混合物で、精巣がん、扁平上皮がん、各種リンパ腫の治療に使用されます。

さらに、進行中の製品承認や、提携、共同研究、製品上市、事業拡大など、市場参入企業が実施する戦略的イニシアティブは、予測期間中の市場成長を促進すると予想されます。例えば、2021年7月、AbbVie Inc.は、米国FDAがDALVANCEを出生時からの小児患者における急性細菌性皮膚と皮膚構造感染症の治療として承認したと発表しました。さらに、2020年7月、Sandoz International GmbHは、Cubicinのジェネリック医薬品であるDaptomycin注射液500mgを、複雑な皮膚・皮膚構造感染症と数種類の血流感染症の成人患者の治療として米国市場に導入すると発表しました。

ペプチド抗生物質市場レポートハイライト

• 非リボソーム合成ペプチド抗生物質セグメントが市場を独占し、2024年の世界売上高の72.79%を占めました。
• 病院薬局セグメントが市場を独占し、2024年の市場シェアは43.96%。
• アジア太平洋は、感染症の流行の増加、大規模な患者プールの利用可能性などの要因により、予測期間中に最も高いCAGRを示すと予想されます。
• 北米のペプチド抗生物質市場は、院内細菌性肺炎（HABP）や人工呼吸器関連細菌性肺炎（VABP）のような複雑な感染症に対処するための効果的なソリューションに対する需要の増加を背景に、着実に成長しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ペプチド抗生物質市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ペプチド抗生物質市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析
• パイプライン分析

第4章 ペプチド抗生物質市場：製品別、推定・動向分析

• セグメントダッシュボード
• 世界のペプチド抗生物質市場：製品変動分析
• 製品別収益
• リボソーム合成ペプチド抗生物質
• 非リボソーム合成ペプチド抗生物質

第5章 ペプチド抗生物質市場：疾患別、推定・動向分析

• セグメントダッシュボード
• 世界のペプチド抗生物質市場：疾病変動分析
• 疾患別、収益別
• 皮膚感染症
• HABP/VABP
• 血流感染症
• その他

第6章 ペプチド抗生物質市場：投与経路別、推定・動向分析

• セグメントダッシュボード
• 世界のペプチド抗生物質市場：投与経路変動分析
• 投与経路別、収益
• 経口
• 注射
• 局所
• その他

第7章 ペプチド抗生物質市場：流通チャネル別、推定・動向分析

• セグメントダッシュボード
• 世界のペプチド抗生物質市場：流通チャネル変動分析
• 流通チャネル別、収益
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 ペプチド抗生物質市場：製品、疾患、投与経路、流通チャネルによる地域別、推定・動向分析

• 地域ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要企業の市場シェア分析、2024年
  • Pfizer Inc.
  • Teva Pharmaceuticals Industries Limited.
  • AbbVie Inc.
  • Merck &Co., Inc.
  • The Menarini Group
  • Sanofi
  • Eli Lilly and Company
  • GSK Plc.
  • NPS Pharmaceuticals
  • Xellia Pharmaceuticals

List of Tables

• Table 1 List of secondary sources
• Table 2 List of Abbreviations
• Table 3 List of key distributors
• Table 4 List of other companies
• Table 5 List of key emerging company's/technology disruptors/innovators
• Table 6 North America Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
• Table 7 North America Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 8 North America Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 9 North America Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 10 North America Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 11 U.S. Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 12 U.S. Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 13 U.S. Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 14 U.S. Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 15 Canada Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 16 Canada Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 17 Canada Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 18 Canada Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 19 Mexico Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 20 Mexico Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 21 Mexico Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 22 Mexico Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 23 Europe Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
• Table 24 Europe Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 25 Europe Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 26 Europe Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 27 Europe Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 U.K. Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 29 U.K. Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 30 UK Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 31 U.K. Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Germany Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 33 Germany Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 34 Germany Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 35 Germany Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 36 France Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 37 France Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 38 France Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 39 France Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 40 Spain Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 41 Spain Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 42 Spain Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 43 Spain Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Italy Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 45 Italy Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 46 Italy Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 47 Italy Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 48 Denmark Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 49 Denmark Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 50 Denmark Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 51 Denmark Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 52 Sweden Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 53 Sweden Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 54 Sweden Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 55 Sweden Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 56 Norway Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 57 Norway Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 58 Norway Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 59 Norway Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 64 Japan Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 65 Japan Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 66 Japan Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 67 Japan Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 68 China Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 69 China Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 70 China Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 71 China Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 72 India Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 73 India Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 74 India Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 75 India Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Australia Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 77 Australia Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 78 Australia Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 79 Australia Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 80 South Korea Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 81 South Korea Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 82 South Korea Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 83 South Korea Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 84 Thailand Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 85 Thailand Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 86 Thailand Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 87 Thailand Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 88 Latin America Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
• Table 89 Latin America Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 90 Latin America Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 91 Latin America Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 92 Latin America Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 93 Brazil Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 94 Brazil Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 95 Brazil Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 96 Brazil Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 97 Argentina Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 98 Argentina Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 99 Argentina Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 100 Argentina Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 101 MEA Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
• Table 102 MEA Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 103 MEA Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 104 MEA Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 105 MEA Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 106 South Africa Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 107 South Africa Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 108 South Africa Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 109 South Africa Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 111 Saudi Arabia Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 114 UAE Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 115 UAE Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 116 UAE Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 117 UAE Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 118 Kuwait Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
• Table 119 Kuwait Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
• Table 120 Kuwait Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 121 Kuwait Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Peptide antibiotics market Segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Peptide antibiotics market snapshot
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook, revenue, 2024 (USD Million)
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Peptide Antibiotics market driver impact
• Fig. 14 Peptide antibiotics market restraint impact
• Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 16 Industry Analysis - Porter's Five Forces
• Fig. 17 Peptide antibiotics market: Product outlook and key takeaways
• Fig. 18 Peptide antibiotics market: Product movement analysis & market share 2024 & 2030
• Fig. 19 Ribosomal synthesized peptide antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Non-ribosomal synthesized peptide antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Peptide Antibiotics market: Disease outlook and key takeaways
• Fig. 22 Peptide Antibiotics market: Disease movement analysis & market share 2024 & 2030
• Fig. 23 Skin infection market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 HABP/VABP market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Blood stream infections market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Peptide antibiotics market: Route of administration outlook and key takeaways
• Fig. 28 Peptide antibiotics market: Route of administration movement analysis & market share 2024 & 2030
• Fig. 29 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Topical market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Peptide antibiotics market: Distribution channel outlook and key takeaways
• Fig. 34 Peptide antibiotics market: Distribution channel movement analysis & market share 2024 & 2030
• Fig. 35 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Global peptide antibiotics market: Regional movement analysis
• Fig. 39 Global peptide antibiotics market: Regional outlook and key takeaways
• Fig. 40 Global peptide antibiotics market share and leading players
• Fig. 41 North America, by country
• Fig. 42 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 U.S. key country dynamics
• Fig. 44 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Canada key country dynamics
• Fig. 46 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Mexico key country dynamics
• Fig. 48 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 UK key country dynamics
• Fig. 51 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Germany key country dynamics
• Fig. 53 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 France key country dynamics
• Fig. 55 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Italy key country dynamics
• Fig. 57 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Spain key country dynamics
• Fig. 59 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Denmark key country dynamics
• Fig. 61 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Sweden key country dynamics
• Fig. 63 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Norway key country dynamics
• Fig. 65 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 China key country dynamics
• Fig. 68 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Japan key country dynamics
• Fig. 70 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 India key country dynamics
• Fig. 72 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Thailand key country dynamics
• Fig. 74 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 South Korea key country dynamics
• Fig. 76 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Australia key country dynamics
• Fig. 78 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Brazil key country dynamics
• Fig. 81 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Argentina key country dynamics
• Fig. 83 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 South Africa key country dynamics
• Fig. 86 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Saudi Arabia key country dynamics
• Fig. 88 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 UAE key country dynamics
• Fig. 90 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Kuwait key country dynamics
• Fig. 92 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Market share Analysis of key market players, 2024

Peptide Antibiotics Market Growth & Trends:

The global peptide antibiotics market size is estimated to reach USD 6.64 billion by 2030, expanding at a CAGR of 5.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness growth opportunities owing to factors such as the increasing research and development activities in field of peptide antibiotics coupled with high number of drug approvals. Moreover, surge in cases of antimicrobial resistance cases and possibility of side effects from the conventional antibiotics are also expected to drive the market during the forecast period.

Increasing prevalence of cancer and other infectious diseases are expected to propel the growth over the forecast period. For instance, according to the CDC, United States reported 1,752,735 new cancer cases along with 599,589 deaths in 2019. For every 100,000 people, 439 new cases were found and 146 people died due to cancer. Further, according to Globocan 2020, U.K. had 457,960 new cases with 179,648 deaths in 2020. The most common types of malignancies were breast, prostate cancer and Non-Hodgkin's lymphoma.

There are some of the peptide antibiotics which are used to treat cancers such as, NHL, Hodgkin's lymphoma, and certain types of skin malignancies. According to Globocan 2020, there were 5,44,352 Non-Hodgkin lymphoma cases and 83,087 Hodgkin's lymphoma cases. The efficiency of various existing products is expected to result into higher revenues owing to doctor recommendations . For instance, BLEOMYCIN for injection USP is the mixture of cytotoxic glycopeptide antibiotics that is isolated from Streptomyces verticillus and is used for the treatment of testicular carcinoma, squamous cell carcinoma, and various types of lymphomas.

Moreover, ongoing product approvals and strategic initiatives undertaken by market players such as partnerships, collaborations, product launches, and expansions are expected to fuel market growth during forecast period. For instance, in July 2021, AbbVie Inc announced that the U.S. FDA approved DALVANCE for the treatment of acute bacterial skin and skin structure infections in pediatric patients from birth. Moreover, in July 2020, Sandoz International GmbH announced introduction of Daptomycin injection 500 mg, a generic version of Cubicin, in the U.S. market for the treatment of adult patients with complicated skin and skin structure infections and several type of bloodstream infections.

Peptide Antibiotics Market Report Highlights:

• The non-ribosomal synthesized peptide antibiotics segment dominated the market and accounted for 72.79% of the global revenue in 2024.
• The hospital pharmacies segment dominated the market with a market share of 43.96% in 2024.
• Asia Pacific region is expected to witness the highest CAGR over the forecast period owing to factors such as, rising prevalence of infectious diseases, and availability of large patient pool
• The North America peptide antibiotics market is growing steadily, driven by increasing demand for effective solutions to combat complex infections such as hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Disease
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and disease outlook
  • 2.2.2. Route of administration and distribution channel outlook
• 2.3. Competitive Insights

Chapter 3. Peptide Antibiotics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High prevalence of microbial resistance
    • 3.2.1.2. Rising investment in R&D of novel drug
    • 3.2.1.3. Technological advancement in peptide antibiotics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Side-effects associated with drug
• 3.3. Peptide Antibiotics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pipeline Analysis

Chapter 4. Peptide Antibiotics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Peptide Antibiotics Market: Product Movement Analysis
• 4.3. Global Peptide Antibiotics Market Estimates and Forecasts, By Product Revenue (USD Million)
• 4.4. Ribosomal Synthesized Peptide Antibiotics
  • 4.4.1. Ribosomal synthesized peptide antibiotics market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Non-ribosomal Synthesized Peptide Antibiotics
  • 4.5.1. Non-ribosomal synthesized peptide antibiotics market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Peptide Antibiotics Market: Disease Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Peptide Antibiotics Market: Disease Movement Analysis
• 5.3. Global Peptide Antibiotics Market Estimates and Forecasts, By Disease, Revenue (USD Million)
• 5.4. Skin Infection
  • 5.4.1. Skin Infection market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. HABP/VABP
  • 5.5.1. HABP/VABP market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Blood Stream Infections
  • 5.6.1. Blood Stream Infections market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Peptide Antibiotics Market: Route of Administration Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Peptide Antibiotics Market: Route of Administration Movement Analysis
• 6.3. Global Peptide Antibiotics Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 6.4. Oral
  • 6.4.1. Oral market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Injectable
  • 6.5.1. Injectable market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Topical
  • 6.6.1. Topical market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Peptide Antibiotics Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Peptide Antibiotics Market: Distribution Channel Movement Analysis
• 7.3. Global Peptide Antibiotics Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 7.4. Hospitals Pharmacies
  • 7.4.1. Hospitals pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Peptide Antibiotics Market: Regional Estimates & Trend Analysis By Product, Disease, Route of Administration, and Distribution Channel

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company market share analysis, 2024
  • 9.3.2. Pfizer Inc.
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Teva Pharmaceuticals Industries Limited.
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. AbbVie Inc.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Merck & Co., Inc.
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. The Menarini Group
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Sanofi
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Eli Lilly and Company
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. GSK Plc.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. NPS Pharmaceuticals
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Xellia Pharmaceuticals
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives